GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Savant and Stoney, love them Blues Brothers!
[/QUOTE]
Such a good movie--the car chases are really good.//
Iridium price target raised to $60 from $51 at Raymond James 08:08 IRDM Raymond James
Iridium price target raised to $60 from $51 at Raymond James 08:08 IRDM Raymond James
An opportunity in breasts?
B. Riley sees 'major tailwind' for Establishment Labs in 2023 07:47 ESTA, JNJ B. Riley analyst Neil Chatterji believes Establishment Labs' planned commercial launch of Motiva into the U.S. market will be a "major tailwind" in 2023, with the company positioned to take share with its "differentiated smooth and natural feel premium implants." The U.S. market is almost half the $1.5B global breast augmentation market, and 80% of the market is aesthetic procedures, Chatterji tells investors in a research note. Motiva should likely be well received by the U.S. plastic surgeon community upon expected approval and launch, particularly given its sub-1% complication rates historically over more than a decade versus much higher competitor rates, and its natural feel and look, says the analyst. He thinks Johnson & Johnson's (JNJ) Mentor unit and AbbVie's (ABBV) Allergan Aesthetics business unit are not a significant focus for either parent company with limited innovation investments, which makes it possible for Establishment to take share from both over time. Chatterji keeps a Buy rating on Establishment Labs with a $107 price target following yesterday's short report.
ESTA-$51.00 (don't see much reaction to short report though)
B. Riley sees 'major tailwind' for Establishment Labs in 2023 07:47 ESTA, JNJ B. Riley analyst Neil Chatterji believes Establishment Labs' planned commercial launch of Motiva into the U.S. market will be a "major tailwind" in 2023, with the company positioned to take share with its "differentiated smooth and natural feel premium implants." The U.S. market is almost half the $1.5B global breast augmentation market, and 80% of the market is aesthetic procedures, Chatterji tells investors in a research note. Motiva should likely be well received by the U.S. plastic surgeon community upon expected approval and launch, particularly given its sub-1% complication rates historically over more than a decade versus much higher competitor rates, and its natural feel and look, says the analyst. He thinks Johnson & Johnson's (JNJ) Mentor unit and AbbVie's (ABBV) Allergan Aesthetics business unit are not a significant focus for either parent company with limited innovation investments, which makes it possible for Establishment to take share from both over time. Chatterji keeps a Buy rating on Establishment Labs with a $107 price target following yesterday's short report.
ESTA-$51.00 (don't see much reaction to short report though)
Van, MVST?
Cerberus Cyber initiated with an Overweight at Cantor Fitzgerald 07:27 CISO
Optinose assumed with a Buy, $5 price target at Jefferies 08:31 OPTN
Norwegian Cruise shares have 120% potential upside, says Tigress Financial 09:20 NCLH Tigress Financial analyst Ivan Feinseth reiterates a Strong Buy rating on Norwegian Cruise Line and initiated a $32 12-month price target on the shares. Norwegian is best positioned to benefit from a "significant post-pandemic travel recovery and re-accelerating cruise industry growth," Feinseth tells investors in a research note. The analyst says the company continues to represent "the most compelling value with the most upside versus its publicly traded industry peers." The stock has "significant upside," with a potential return of over 120% from current levels, contends Feinseth.
Optinose assumed with a Buy, $5 price target at Jefferies 08:31 OPTN
Norwegian Cruise shares have 120% potential upside, says Tigress Financial 09:20 NCLH Tigress Financial analyst Ivan Feinseth reiterates a Strong Buy rating on Norwegian Cruise Line and initiated a $32 12-month price target on the shares. Norwegian is best positioned to benefit from a "significant post-pandemic travel recovery and re-accelerating cruise industry growth," Feinseth tells investors in a research note. The analyst says the company continues to represent "the most compelling value with the most upside versus its publicly traded industry peers." The stock has "significant upside," with a potential return of over 120% from current levels, contends Feinseth.
Ted- The co just received Biden $'s on wed.Not sure how much....
LTO, lithium-ion battery system to be developed by Microvast, with extremely high C-rate capability and long cycle life of up to 20,000 cycles under normal operating conditions, will be critical to enable the high-power, ultrafast charging and heavy duty use solution that the consortium is chartered to deliver. Microvast's LTO battery system is expected to achieve energy density, ensuring that sufficient energy is delivered for the application, while meeting space and weight restrictions.
I think Fedex was $160 that day.
FDX----> $151
--->Never doubt the Savant Stoney
